Healx raised $47 million in a Series C funding round led by R42 Group and Atomico to develop treatments for rare diseases including neurofibromatosis Type 1.

Aug 01, 2024•over 1 year ago

Amount Raised

$47 Million

Round Type

series c

CambridgeTherapeuticsArtificial IntelligenceBiotechnologyHealth Care

Investors

Vu Venture PartnersO2hAyana CapitalBtovGlobal BrainJonathan MilnerBaldertonAtomicoR42 Group

Description

Healx has announced the completion of a $47 million Series C financing to support its pipeline of medicines. The funding will advance the lead program HLX-1502 through a Phase 2 clinical trial for neurofibromatosis Type 1.

Company Information

Company

Healx

Location

Cambridge, England, United Kingdom

About

Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet discovery platform. Healx is committed to harnessing AI to identify and develop new therapeutic opportunities for patients with significant unmet medical needs.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends